Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

休市中 09-19 16:00:00 EDT

15.59

-0.52

-3.23%

盘后15.61

+0.02+0.13%

19:59 EDT

最高16.85	最低15.37	成交量1,526万
今开16.42	昨收16.11	日振幅9.19%
总市值16.74亿	流通市值15.91亿	总股本1.07亿
成交额2.45亿	换手率14.96%	流通股本1.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":15.59,"timestamp":1758312000000,"preClose":16.11,"halted":0,"volume":15264365,"hourTrading":{"tag":"盘后","latestPrice":15.61,"preClose":15.59,"latestTime":"19:59 EDT","volume":1286331,"amount":20055608.8761,"timestamp":1758326350294},"delay":0,"floatShares":102023156,"shares":107346886,"eps":-4.68306,"marketStatus":"休市中","change":-0.52,"latestTime":"09-19 16:00:00 EDT","open":16.42,"high":16.85,"low":15.37,"amount":244749851.122455,"amplitude":0.091868,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.68306,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1758528000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1462507200000,"exchange":"NASDAQ","adjPreClose":16.11,"preHourTrading":{"tag":"盘前","latestPrice":16.41,"preClose":16.11,"latestTime":"09:29 EDT","volume":668532,"amount":10756504.056084,"timestamp":1758288599999},"postHourTrading":{"tag":"盘后","latestPrice":15.61,"preClose":15.59,"latestTime":"19:59 EDT","volume":1286331,"amount":20055608.8761,"timestamp":1758326350294},"volumeRatio":2.001976156471375,"impliedVol":0.9111,"impliedVolPercentile":0.544},"requestUrl":"/m/hq/s/NTLA/tweets","defaultTab":"tweets","newsList":[{"id":"2568470438","title":"Sector Update: Health Care Stocks Advance Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2568470438","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568470438?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:10","pubTimestamp":1758201058,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund  0.1% higher and the iShares Biotechnology ETF  up 1%.89bio  stock was up more than 85% after the company said it has agreed to be acquired by Roche for $2.4 billion or a price of $14.50 per share in cash, a premium of about 79% above its closing Wednesday stock price.Novo Nordisk  shares were up more than 7% after the company said its injectable Ozempic was linked to a 23% lower risk of heart attack, stroke, and death compared with dulaglutide in US Medicare patients with type 2 diabetes and cardiovascular disease.Intellia Therapeutics  shares were up more than 5% after the company said it has completed patient enrollment in a phase 3 study of lonvoguran ziclumeran for hereditary angioedema treatment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"行业更新：医疗保健股周四盘前上涨","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","NVO","BK4556","NTLA","BK4581","NVO.AU","IE00BKVL7J92.USD","BK4585","ETNB","BK4007","BK4532","IE00BZ1G4Q59.USD","XBI","IBB","LU0154236417.USD","BK4139","XLV","LU1861559042.SGD","LU1093756325.SGD","LU1093756168.USD","BK4599","BK4535","BK4588","LU1861558580.USD"],"gpt_icon":1},{"id":"1175675607","title":"Intellia Therapeutics完成遗传性血管性水肿药物Lonvoguran Ziclumeran (Lonvo-Z)全球3期临床试验Haelo研究的患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1175675607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175675607?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:30","pubTimestamp":1758195054,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics已完成其治疗遗传性血管性水肿药物Lonvoguran Ziclumeran (Lonvo-Z)的全球3期临床试验Haelo研究的患者招募工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1861558580.USD","BK4535","NTLA","LU1861559042.SGD","BK4588","BK4139","BK4556"],"gpt_icon":0},{"id":"2568472518","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.54%报12.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568472518","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568472518?lang=zh_cn&edition=full","pubTime":"2025-09-17 21:31","pubTimestamp":1758115909,"startTime":"0","endTime":"0","summary":"北京时间2025年09月17日21时31分，Intellia Therapeutics, Inc.股票出现波动，股价快速上涨5.54%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917213149a4cbc586&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861559042.SGD","BK4007","BK4539","LU1861558580.USD","BK4556","BK4585","LENZ","BK4535","NTLA","BK4588","BK4139"],"gpt_icon":0},{"id":"2557520435","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大跌5.04%报10.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557520435","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557520435?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:52","pubTimestamp":1754661136,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时52分，Intellia Therapeutics, Inc.股票出现异动，股价急速下跌5.04%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821521694d7d1a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861559042.SGD","BK4585","BK4539","LENZ","BK4535","BK4588","BK4007","LU1861558580.USD","BK4556","BK4139","NTLA"],"gpt_icon":0},{"id":"2557593195","title":"RBC Cuts Price Target on Intellia Therapeutics to $21 From $25, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2557593195","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557593195?lang=zh_cn&edition=full","pubTime":"2025-08-08 02:38","pubTimestamp":1754591934,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) has an average rating of overweight and mean price target of $34.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"加拿大皇家银行将Intellia Therapeutics目标价从25美元下调至21美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTLA"],"gpt_icon":0},{"id":"2557556145","title":"Intellia Therapeutics' Shares Fall After Q2 Net Loss Narrows, Revenue Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2557556145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557556145?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:47","pubTimestamp":1754574451,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics' (NTLA) shares were down 1.3% in recent Thursday trading after the company reported a Q2 net loss of $0.98 per diluted share, narrower than its loss of $1.52 a year earlier.Analy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Intellia Therapeutics第二季度净亏损收窄、收入增加后股价下跌","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTLA"],"gpt_icon":0},{"id":"2557256550","title":"Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Net Loss $0.98 a Share, vs. FactSet Est of $1.02 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2557256550","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557256550?lang=zh_cn&edition=full","pubTime":"2025-08-07 19:41","pubTimestamp":1754566889,"startTime":"0","endTime":"0","summary":"Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Net Loss $0.98 a Share, vs. FactSet Est of $1.02 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"财报(NTLA)Intellia Therapeutics公布第二季度每股净亏损0.98美元，而FactSet预计亏损1.02美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTLA"],"gpt_icon":0},{"id":"2557557790","title":"Intellia Therapeutics Q2 2025 EPS $(0.98) Beats $(1.03) Estimate, Sales $14.245M Beat $12.256M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557557790","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557557790?lang=zh_cn&edition=full","pubTime":"2025-08-07 19:31","pubTimestamp":1754566275,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Q2 2025 EPS $(0.98) Beats $(1.03) Estimate, Sales $14.245M Beat $12.256M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Intellia Therapeutics 2025年第二季度每股收益(0.98)美元超出预期(1.03)美元，销售额1,424.5万美元超出预期1,225.6万美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46958068/intellia-therapeutics-q2-2025-eps-0-98-beats-1-03-estimate-sales-14-245m-beat-12-256m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA"],"gpt_icon":0},{"id":"2557330374","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大跌5.05%报11.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557330374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557330374?lang=zh_cn&edition=full","pubTime":"2025-08-06 22:31","pubTimestamp":1754490668,"startTime":"0","endTime":"0","summary":"北京时间2025年08月06日22时31分，Intellia Therapeutics, Inc.股票出现异动，股价急速下挫5.05%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.51%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080622310894d393b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4588","BK4556","BK4139","NTLA","BK4585","LU1861558580.USD","LENZ","BK4539","BK4007","LU1861559042.SGD"],"gpt_icon":0},{"id":"2555050567","title":"Intellia Therapeutics, Inc.盘中异动 快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555050567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555050567?lang=zh_cn&edition=full","pubTime":"2025-07-29 23:20","pubTimestamp":1753802436,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日23时20分，Intellia Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507292320379725ae9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4539","NTLA","BK4535","LU1861558580.USD","BK4588","BK4556","LENZ","BK4007","LU1861559042.SGD","BK4139"],"gpt_icon":0},{"id":"2549531181","title":"RBC Cuts Price Target on Intellia Therapeutics to $25 From $30, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2549531181","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549531181?lang=zh_cn&edition=full","pubTime":"2025-07-07 19:46","pubTimestamp":1751888797,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) has an average rating of overweight and mean price target of $36.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"RBC将Intellia Therapeutics目标价从30美元下调至25美元，维持跑赢大盘和投机风险","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTLA"],"gpt_icon":0},{"id":"2546422837","title":"Intellia Therapeutics, Inc.盘中异动 急速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546422837","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546422837?lang=zh_cn&edition=full","pubTime":"2025-06-27 22:09","pubTimestamp":1751033374,"startTime":"0","endTime":"0","summary":"北京时间2025年06月27日22时09分，Intellia Therapeutics, Inc.股票出现异动，股价快速拉升5.10%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627220934a4c1696d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861559042.SGD","LU1861558580.USD","BK4588","BK4007","BK4585","BK4535","LENZ","BK4556","BK4539","BK4139","NTLA"],"gpt_icon":0},{"id":"2540004776","title":"加拿大投资银行集团：维持Intellia Therapeutics(NTLA.US)评级，由买入调整至买入评级, 目标价由74.00美元调整至54.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2540004776","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540004776?lang=zh_cn&edition=full","pubTime":"2025-06-03 19:41","pubTimestamp":1748950911,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：维持Intellia Therapeutics(NTLA.US)评级，由买入调整至买入评级, 目标价由74.00美元调整至54.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/03194150837064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2539250287","title":"Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250287","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539250287?lang=zh_cn&edition=full","pubTime":"2025-05-29 20:26","pubTimestamp":1748521617,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.Shares of the company were down by more than 20% in recent Thursday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Intellia表示NTLA-2002后期研究进展顺利，用于ATTRv-PN的Nex-Z进展顺利","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4139","BK4585","SSI","BK4556","LU1861558580.USD","PN","LU1861559042.SGD","BK4588","BK4096","NTLA"],"gpt_icon":1},{"id":"2539252572","title":"Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2539252572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539252572?lang=zh_cn&edition=full","pubTime":"2025-05-29 19:18","pubTimestamp":1748517505,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) has an average rating of overweight and mean price target of $38.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"Wedbush将Intellia Therapeutics目标价从10美元下调至7美元，维持中性评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTLA"],"gpt_icon":0},{"id":"2537483134","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大跌5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537483134","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537483134?lang=zh_cn&edition=full","pubTime":"2025-05-23 21:31","pubTimestamp":1748007070,"startTime":"0","endTime":"0","summary":"北京时间2025年05月23日21时31分，Intellia Therapeutics, Inc.股票出现异动，股价快速跳水5.39%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.84%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。消息层面，截至21时31分，《HC Wainwright & Co.：重申Intellia Therapeutics评级》资讯为影响Intellia Therapeutics, Inc.的重要信息。该信息摘要如下：HC Wainwright&Co.：重申Intellia Therapeutics评级，由买入调整至买入评级,目标价由30.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523213110aa2c981c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4588","BK4556","BK4139","NTLA","BK4585","LU1861558580.USD","LENZ","BK4539","BK4007","LU1861559042.SGD"],"gpt_icon":0},{"id":"2537958102","title":"Intellia Therapeutics, Inc.盘中异动 下午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537958102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537958102?lang=zh_cn&edition=full","pubTime":"2025-05-22 01:20","pubTimestamp":1747848015,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日01时20分，Intellia Therapeutics, Inc.股票出现波动，股价大幅跳水5.05%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.00%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。消息层面，截至01时20分，《HC Wainwright & Co.：重申Intellia Therapeutics评级》资讯为影响Intellia Therapeutics, Inc.的重要信息。该信息摘要如下：HC Wainwright&Co.：重申Intellia Therapeutics评级，由买入调整至买入评级,目标价由30.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522012016aa2c95b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","NTLA","BK4556","BK4007","BK4539","BK4139","BK4588","LENZ","LU1861559042.SGD","BK4535","BK4585"],"gpt_icon":0},{"id":"2536641858","title":"Intellia Therapeutics, Inc.盘中异动 大幅上涨5.19%报9.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536641858","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536641858?lang=zh_cn&edition=full","pubTime":"2025-05-20 23:17","pubTimestamp":1747754275,"startTime":"0","endTime":"0","summary":"北京时间2025年05月20日23时17分，Intellia Therapeutics, Inc.股票出现异动，股价快速拉升5.19%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。消息层面，截至23时17分，《HC Wainwright & Co.：重申Intellia Therapeutics评级》资讯为影响Intellia Therapeutics, Inc.的重要信息。该信息摘要如下：HC Wainwright&Co.：重申Intellia Therapeutics评级，由买入调整至买入评级,目标价由30.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520231755975faa64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU1861558580.USD","BK4588","BK4556","BK4535","LENZ","NTLA","BK4139","BK4539","LU1861559042.SGD","BK4007"],"gpt_icon":0},{"id":"2536614445","title":"HC Wainwright & Co.：重申Intellia Therapeutics评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2536614445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536614445?lang=zh_cn&edition=full","pubTime":"2025-05-20 19:23","pubTimestamp":1747740197,"startTime":"0","endTime":"0","summary":"HC Wainwright&Co.：重申Intellia Therapeutics评级，由买入调整至买入评级,目标价由30.00美元调整至30.00美元。Intellia Therapeutics公司简介：Intellia Therapeutics是一家基因编辑公司，致力于开发基于Crispr/Cas9的疗法。Crispr/Cas9是Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-associated protein9的缩写，是一种精确改变基因组DNA特定序列的革命性技术。Intellia致力于利用这项技术治疗基因定义的疾病。Intellia已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜Regeneron和宽膜Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520193558a6e603b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2536824680","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.06%报8.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536824680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536824680?lang=zh_cn&edition=full","pubTime":"2025-05-19 21:34","pubTimestamp":1747661695,"startTime":"0","endTime":"0","summary":"北京时间2025年05月19日21时34分，Intellia Therapeutics, Inc.股票出现波动，股价急速拉升5.06%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519213455a6e4d108&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LENZ","BK4539","LU1861558580.USD","BK4588","BK4535","BK4007","BK4139","BK4556","LU1861559042.SGD","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":0.3651},{"period":"1month","weight":0.5269},{"period":"3month","weight":0.6946},{"period":"6month","weight":0.7322},{"period":"1year","weight":-0.3201},{"period":"ytd","weight":0.337}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.1168},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.1624},{"period":"ytd","weight":0.1324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.000449},{"month":2,"riseRate":0.666667,"avgChangeRate":0.066917},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.068465},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.038358},{"month":5,"riseRate":0.222222,"avgChangeRate":0.002269},{"month":6,"riseRate":0.9,"avgChangeRate":0.229655},{"month":7,"riseRate":0.6,"avgChangeRate":0.044195},{"month":8,"riseRate":0.5,"avgChangeRate":0.02106},{"month":9,"riseRate":0.2,"avgChangeRate":-0.025616},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.087409},{"month":11,"riseRate":0.666667,"avgChangeRate":0.118994},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.093181}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况